In an analysis of data from the phase 3 IMPACT trial of sipuleucel-T, improved overall survival was seen in patients who showed an immunoglobulin G response to the primary antigen and any 3 secondary antigens.
IMPACT, Immunotherapy Prostate Adenocarcinoma Treatment.
Adapted from Drake CG et al. ASCO GU abstract 88. J Clin Oncol. 2014;32(4)(suppl).